Table 5.
Demographic, clinical, and laboratory values in 725 PD patients, according to categories of GA.
| Variables | All | GA Categories | P value | ||||||
|---|---|---|---|---|---|---|---|---|---|
| <12.0 | 12.0 to 13.9 | 14.0 to 15.9 | 16.0 to 17.9 | 18.0 to 19.9 | 20.0 to 21.9 | ≥22 | |||
| n (male%) | 725 (70.1) | 42 (61.9) | 132 (71.2) | 164 (79.3) | 150 (68.0) | 100 (71.0) | 63 (66.7) | 74 (66.2) | 0.153 |
| Age (years) | 63.5 ± 11.7 | 58.5 ± 12.2 | 61.7 ± 11.9 | 64.4 ± 11.9 | 64.4 ± 11.4 | 63.6 ± 11.6 | 63.8 ± 11.0 | 65.0 ± 10.9 | 0.028 |
| PD duration (m) | 29 [14–53] | 27 [15–54] | 24 [13–49] | 24 [13–49] | 33 [14–55] | 37 [19–64] | 29 [12–57] | 27 [13–49] | 0.166 |
| Type 1 (%) | 12.1 | 4.7 | 5.3 | 9.7 | 14.0 | 19.0 | 14.3 | 18.9 | 0.006 |
| CVD comorbidity (%) | 25.8 | 16.7 | 22.7 | 27.4 | 26.7 | 30.0 | 17.5 | 32.4 | 0.241 |
| Smoking (%) | 11.0 | 13.5 | 10.9 | 6.9 | 11.5 | 17.2 | 5.5 | 14.0 | 0.193 |
| Insulin (%) | 37.5 | 30.5 | 20.6 | 27.6 | 39.2 | 47.4 | 50.0 | 65.1 | <0.0001 |
| Oral antidiabetic agents (%) | 43.3 | 37.1 | 36.3 | 46.5 | 41.2 | 49.5 | 45.3 | 46.2 | 0.478 |
| Diet therapy alone (%) | 32.0 | 38.9 | 47.5 | 37.2 | 31.8 | 20.8 | 19.6 | 15.9 | <0.0001 |
| Antihypertensive agents (%) | 83.6 | 84.2 | 87.0 | 84.6 | 84.8 | 76.9 | 89.1 | 76.9 | 0.293 |
| HD combination (%) | 23.7 | 21.4 | 19.7 | 23.1 | 24.6 | 34.0 | 15.8 | 24.3 | 0.163 |
| Anuric (%) | 20.8 | 13.9 | 15.7 | 18.0 | 25.0 | 19.4 | 21.7 | 33.9 | 0.131 |
| Total Kt/V | 1.7 ± 0.7 | 1.7 ± 0.6 | 1.7 ± 0.6 | 1.7 ± 0.6 | 1.8 ± 0.9 | 1.6 ± 0.7 | 1.9 ± 0.9 | 1.6 ± 0.6 | 0.224 |
| 2.5% glucose dialysate use (%) | 43.6 | 32.4 | 35.8 | 34.9 | 45.9 | 61.3 | 45.6 | 52.9 | 0.0007 |
| Icodextrin dialysate use (%) | 53.6 | 54.1 | 60.0 | 54.1 | 51.1 | 46.6 | 52.6 | 55.9 | 0.643 |
| D/P Cr | 0.67 ± 0.13 | 0.71 ± 0.14 | 0.69 ± 0.13 | 0.66 ± 0.15 | 0.66 ± 0.12 | 0.67 ± 0.11 | 0.66 ± 0.13 | 0.67 ± 0.11 | 0.273 |
| APD user (%) | 46.2 | 44.7 | 43.3 | 43.4 | 47.7 | 57.3 | 42.1 | 44.8 | 0.439 |
| Body mass index (kg/m2) | 24.3 ± 3.7 | 25.1 ± 3.7 | 24.9 ± 3.9 | 24.1 ± 3.4 | 24.3 ± 3.6 | 23.9 ± 3.7 | 24.7 ± 4.6 | 23.4 ± 3.5 | 0.108 |
| Hemoglobin (g/dL) | 10.8 ± 1.4 | 10.8 ± 1.3 | 10.7 ± 1.3 | 10.9 ± 1.4 | 10.8 ± 1.4 | 10.6 ± 1.4 | 11.0 ± 1.4 | 10.6 ± 1.4 | 0.572 |
| Serum albumin (g/dL) | 3.2 ± 0.5 | 3.2 ± 0.5 | 3.2 ± 0.5 | 3.3 ± 0.5 | 3.2 ± 0.5 | 3.2 ± 0.6 | 3.3 ± 0.4 | 3.2 ± 0.6 | 0.391 |
| Total cholesterol (mg/dL) | 172 ± 40 | 170 ± 43 | 173 ± 34 | 173 ± 41 | 172 ± 41 | 168 ± 41 | 174 ± 43 | 170 ± 41 | 0.962 |
| HDL-cholesterol (mg/dL) | 46 ± 17 | 50 ± 23 | 47 ± 14 | 45 ± 14 | 47 ± 20 | 43 ± 14 | 45 ± 16 | 46 ± 24 | 0.351 |
| C-reactive protein (mg/dL) | 0.17 [0.07–0.50] | 0.12 [0.08–0.42] | 0.17 [0.08–0.38] | 0.15 [0.07–0.44] | 0.17 [0.09–0.48] | 0.17 [0.07–0.62] | 0.11 [0.05–0.46] | 0.35 [0.09–1.01] | 0.003 |
| Calcium (mg/dL) | 8.5 ± 0.8 | 8.5 ± 0.8 | 8.6 ± 0.9 | 8.6 ± 0.8 | 8.6 ± 0.8 | 8.5 ± 0.8 | 8.6 ± 0.8 | 8.4 ± 0.9 | 0.498 |
| Phosphate (mg/dL) | 5.3 ± 1.3 | 5.6 ± 1.6 | 5.4 ± 1.3 | 5.3 ± 1.4 | 5.3 ± 1.2 | 5.1 ± 1.2 | 5.0 ± 1.3 | 5.2 ± 1.3 | 0.285 |
| Intact-PTH (pg/mL) | 152 [74–246] | 151 [79–207] | 148 [68–236] | 155 [75–257] | 128 [67–232] | 138 [68–235] | 194 [85–249] | 198 [81–295] | 0.101 |
| Switch to HD, n (%) | 227 (31.3) | 11 (26.2) | 46 (34.8) | 40 (24.4) | 53 (35.3) | 37 (37.0) | 22 (34.9) | 18 (24.3) | 0.215 |
| Death (%) | 15.9 | 12.9 | 12.8 | 12.9 | 16.5 | 14.3 | 14.6 | 30.3 | 0.002 |
| Cardiovascular death | 7.1 | 10.0 | 7.4 | 6.1 | 5.8 | 5.3 | 7.9 | 11.4 | 0.886 |
| Infection-related death | 7.1 | 0 | 3.9 | 5.3 | 9.0 | 6.9 | 5.4 | 18.8 | 0.025 |
CVD, cardiovascular disease; HD, hemodialysis; HDL, high-density lipoprotein; PD, peritoneal dialysis; PTH, parathyroid hormone.